克唑替尼靶向基因ROS1/ALK/MET在恶性间皮瘤中的荧光原位杂交分析 - Suppr | 超能文献

相似文献

1

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma.克唑替尼靶向基因ROS1/ALK/MET在恶性间皮瘤中的荧光原位杂交分析

J Thorac Oncol. 2017 Aug;12(8):e116-e118. doi: 10.1016/j.jtho.2017.03.015.

2

ROS1 rearrangements define a unique molecular class of lung cancers.ROS1 重排定义了一类独特的肺癌分子亚型。

J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.

3

Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.荧光原位杂交（Fish）和免疫组织化学（IHC）在评估 ALK 状态方面的差异与 ALK“临界阳性”重排或高拷贝数有关：这可能是针对 ALK 的治疗策略的一个主要问题。

Ann Oncol. 2015 Jan;26(1):238-244. doi: 10.1093/annonc/mdu484. Epub 2014 Oct 24.

4

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.克唑替尼耐药 ROS1 突变揭示了 ROS1 和 ALK 重排肺癌的预测激酶抑制剂敏感性模型。

Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11.

5

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.BIRC6-ALK，一种在ALK断裂分离FISH阴性肺腺癌中的新型融合基因，对克唑替尼有反应。

J Thorac Oncol. 2015 Jun;10(6):e37-9. doi: 10.1097/JTO.0000000000000467.

6

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.通过综合基因组分析检测具有MET、ALK和ROS1基因组改变的克唑替尼敏感型肺腺癌

Clin Lung Cancer. 2015 Sep;16(5):e105-9. doi: 10.1016/j.cllc.2015.03.002. Epub 2015 Mar 25.

7

An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.间变性淋巴瘤激酶免疫组化阴性但荧光原位杂交阳性的肺腺癌对克唑替尼耐药。

J Thorac Oncol. 2016 Dec;11(12):2248-2252. doi: 10.1016/j.jtho.2016.08.139. Epub 2016 Sep 6.

8

Crizotinib targets in glioblastoma stem cells.克唑替尼在胶质母细胞瘤干细胞中的靶点。

Cancer Med. 2017 Nov;6(11):2625-2634. doi: 10.1002/cam4.1167. Epub 2017 Sep 27.

9

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.对吉非替尼耐药但对克唑替尼敏感的肺腺癌患者，同时存在表皮生长因子受体罕见突变（L861Q）以及ALK/MET/ROS1基因拷贝数增加。

J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37.

10

[Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib].[克唑替尼成功治疗捷克ROS1易位患者]

Klin Onkol. 2016;29(1):63-5. doi: 10.14735/amko201663.

引用本文的文献

1

Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack.临床下一代测序在间皮瘤中的应用：大海捞针

Cancers (Basel). 2023 Dec 6;15(24):5716. doi: 10.3390/cancers15245716.

2

Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma.恶性间皮瘤中 MET 受体过表达与 MET 基因扩增及患者预后的相关性。

Int J Mol Sci. 2021 Nov 28;22(23):12868. doi: 10.3390/ijms222312868.

3

Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer.